Literature DB >> 1913544

Follicular Hurthle cell tumors of the thyroid gland.

M L Carcangiu1, S Bianchi, D Savino, I M Voynick, J Rosai.   

Abstract

A clinicopathologic study of 153 cases of thyroid follicular Hurthle cell tumor (HCT) is presented. Follow-up, available in all cases, ranged from 5 to 26 years (median, 9 years). These neoplasms were divided into three categories on the basis of presence and degree of capsular and vascular invasion, pattern of growth (follicular, trabecular, or solid), nuclear atypia, and necrosis. The categories were benign (90 cases), indeterminate (35 cases), and malignant (28 cases). All the tumors classified histologically as benign or indeterminate behaved in a clinically benign fashion. Of the 28 tumors classified histologically as malignant, 20 had a clinically malignant behavior. At survival analysis, no clinical or pathologic feature among the carcinomas was found to correlate with a fatal outcome. It is concluded that histologic criteria alone can distinguish benign from malignant HCT and that clinical or pathologic feature cannot predict behavior among the malignant tumors.

Entities:  

Mesh:

Year:  1991        PMID: 1913544     DOI: 10.1002/1097-0142(19911101)68:9<1944::aid-cncr2820680917>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

Review 1.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

Review 2.  Mitochondria and cancer.

Authors:  Valdemar Máximo; Jorge Lima; Paula Soares; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2009-04-03       Impact factor: 4.064

Review 3.  Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.

Authors:  B Xu; R Ghossein
Journal:  Eur J Surg Oncol       Date:  2017-05-18       Impact factor: 4.424

4.  Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?

Authors:  H Chen; T L Nicol; M A Zeiger; W C Dooley; P W Ladenson; D S Cooper; M Ringel; S Parkerson; M Allo; R Udelsman
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

Review 5.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

6.  Surgical treatment of Hurthle cell tumors of the thyroid.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

7.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

8.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

9.  Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment.

Authors:  Adolfo Pisanu; Luigi Sias; Alessandro Uccheddu
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

Review 10.  Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis.

Authors:  Pierpaolo Trimboli; Giorgio Treglia; Leo Guidobaldi; Enrico Saggiorato; Giuseppe Nigri; Anna Crescenzi; Francesco Romanelli; Fabio Orlandi; Stefano Valabrega; Ramin Sadeghi; Luca Giovanella
Journal:  Endocrine       Date:  2013-10-03       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.